JPH05503540A - 単斜結晶構造を有する熱―、光―、及び湿気―感受性活性成分を含む錠剤又は糖剤組成物の調製方法 - Google Patents
単斜結晶構造を有する熱―、光―、及び湿気―感受性活性成分を含む錠剤又は糖剤組成物の調製方法Info
- Publication number
- JPH05503540A JPH05503540A JP3513683A JP51368391A JPH05503540A JP H05503540 A JPH05503540 A JP H05503540A JP 3513683 A JP3513683 A JP 3513683A JP 51368391 A JP51368391 A JP 51368391A JP H05503540 A JPH05503540 A JP H05503540A
- Authority
- JP
- Japan
- Prior art keywords
- active ingredient
- tablets
- weight
- known per
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000004480 active ingredient Substances 0.000 title claims abstract description 46
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 239000013078 crystal Substances 0.000 title claims description 9
- 239000008298 dragée Substances 0.000 title abstract description 11
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 25
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 13
- 238000000576 coating method Methods 0.000 claims abstract description 13
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 13
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 13
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 13
- 239000011248 coating agent Substances 0.000 claims abstract description 12
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims abstract description 10
- -1 alkaline earth metal salt Chemical class 0.000 claims abstract description 9
- 239000008240 homogeneous mixture Substances 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 5
- 239000003937 drug carrier Substances 0.000 claims abstract description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 4
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 4
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical class NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 claims description 2
- 229910000020 calcium bicarbonate Inorganic materials 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 2
- 229910052749 magnesium Inorganic materials 0.000 claims 2
- 239000011777 magnesium Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- UBDZFAGVPPMTIT-UHFFFAOYSA-N 2-aminoguanidine;hydron;chloride Chemical compound [Cl-].NC(N)=N[NH3+] UBDZFAGVPPMTIT-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 241000212342 Sium Species 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- 235000010216 calcium carbonate Nutrition 0.000 claims 1
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Inorganic materials [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims 1
- QQFLQYOOQVLGTQ-UHFFFAOYSA-L magnesium;dihydrogen phosphate Chemical compound [Mg+2].OP(O)([O-])=O.OP(O)([O-])=O QQFLQYOOQVLGTQ-UHFFFAOYSA-L 0.000 claims 1
- 235000019691 monocalcium phosphate Nutrition 0.000 claims 1
- 229910000401 monomagnesium phosphate Inorganic materials 0.000 claims 1
- 235000019785 monomagnesium phosphate Nutrition 0.000 claims 1
- 235000002639 sodium chloride Nutrition 0.000 claims 1
- 239000000654 additive Substances 0.000 abstract description 6
- 230000000996 additive effect Effects 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 description 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- 238000000354 decomposition reaction Methods 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 238000007906 compression Methods 0.000 description 8
- 230000006835 compression Effects 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 239000000454 talc Substances 0.000 description 8
- 229910052623 talc Inorganic materials 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 7
- 229920002261 Corn starch Polymers 0.000 description 7
- 229960005070 ascorbic acid Drugs 0.000 description 7
- 235000010323 ascorbic acid Nutrition 0.000 description 7
- 239000011668 ascorbic acid Substances 0.000 description 7
- 239000008120 corn starch Substances 0.000 description 7
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 6
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000008119 colloidal silica Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 239000001034 iron oxide pigment Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000005550 wet granulation Methods 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000005056 compaction Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- QUDJVIVCJPSCQS-UHFFFAOYSA-N 2-(dimethylamino)guanidine hydrochloride Chemical compound Cl.CN(C)NC(=N)N QUDJVIVCJPSCQS-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004484 Briquette Substances 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 108010011222 cyclo(Arg-Pro) Proteins 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- FYUWIEKAVLOHSE-UHFFFAOYSA-N ethenyl acetate;1-ethenylpyrrolidin-2-one Chemical compound CC(=O)OC=C.C=CN1CCCC1=O FYUWIEKAVLOHSE-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000003711 photoprotective effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- SRRKNRDXURUMPP-UHFFFAOYSA-N sodium disulfide Chemical compound [Na+].[Na+].[S-][S-] SRRKNRDXURUMPP-UHFFFAOYSA-N 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Inorganic Compounds Of Heavy Metals (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Bending Of Plates, Rods, And Pipes (AREA)
- Press Drives And Press Lines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
Claims (5)
- 1.単斜結晶構造を有する湿気−、熱−及び光−感受性化合物を含む錠剤又は糖 剤組成物の調製法に関し、活性成分から計算して0.2〜1.5重量部の無水ア ルカリ土類金属塩及び0.5〜2.5重量部の微結晶性セルロース並びに所望に は1又は複数の医薬的に許容できるキャリヤー及び/又は添加剤と共に活性成分 を均質化し、そしてこのようにして得られた均質混合物をそれ自体既知の方法に より錠剤に圧縮し、そして所望により、それ自体既知の方法により前記の得られ た錠剤を被覆することを含んで成る方法。
- 2.アルカリ土類金属塩としてリン酸、炭酸水素カルシウム又はマグネシウム、 リン酸二水素カルシウム又はマグネシウム、炭酸又は硫酸カルシウム又はマグネ シウムを用いることを含んで成る請求の範囲第1項記載の方法。
- 3.活性成分として、下記一般式(I):▲数式、化学式、表等があります▼( I)〔式中、R1,R2及びR3はお互い独立して、水素、ハロゲン又はC1− 4アルキル、ニトロ、C1−4アルコキシ又はトリフルオロメチル基を表わし; R4及びR5はお互い独立して、C1−4アルキル基を表わし; R6及びR7はお互い独立して、水素又はC1−4アルキル基又はC2−4アル ケニル基を表わす〕で表わされる単斜結晶構造を有するアミノグアニジン誘導体 類又は、それらの酸付加塩を用いることを含んで成る請求の範囲第1項記載の方 法。
- 4.活性成分として1−(2,6−ジメチルフェニル)−4,4′−ジメチルア ミノグアニジン塩酸塩を用いることを含んで成る請求の範囲第3項記載の方法。
- 5.活性成分としての1−(2,6−ジメチルフェニル)−4,4′−ジメチル アミノグアニジン塩酸塩と共に、活性成分から計算して0.2〜1.5重量部の 無水リン酸水素カルシウム及び0.5〜2.5重量部の微結晶性セルロース並び に所望には1又は複数の医薬的に許容できるキャリヤー及び/又は添加剤を均質 化し、そしてこのようにして得られた均質混合物をそれ自体既知の方法により錠 剤に圧縮し、そして所望により、それ自体既知の方法により前記の得られた錠剤 を被覆することを含んで成る請求の範囲第1項記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU5314/90 | 1990-08-24 | ||
HU905314A HU206824B (en) | 1990-08-24 | 1990-08-24 | Process for the production of a table crystallizing in the monoclinic system, which contains light-, heat-, and moisture- sensitive active agents |
PCT/HU1991/000039 WO1992003126A1 (en) | 1990-08-24 | 1991-08-23 | Process for the preparation of a tablet or dragee composition containing a heat-, light- and moisture-sensitive active ingredient having monoclinic crystal structure |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH05503540A true JPH05503540A (ja) | 1993-06-10 |
JPH0813736B2 JPH0813736B2 (ja) | 1996-02-14 |
Family
ID=10970061
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP3513683A Expired - Fee Related JPH0813736B2 (ja) | 1990-08-24 | 1991-08-23 | 単斜結晶構造を有する熱―、光―、及び湿気―感受性活性成分を含む錠剤又は糖剤組成物の調製方法 |
Country Status (19)
Country | Link |
---|---|
US (1) | US5322698A (ja) |
EP (1) | EP0500851B1 (ja) |
JP (1) | JPH0813736B2 (ja) |
KR (1) | KR0177493B1 (ja) |
AT (1) | ATE119388T1 (ja) |
CA (1) | CA2067733C (ja) |
CZ (1) | CZ281577B6 (ja) |
DE (1) | DE69108007T2 (ja) |
DK (1) | DK0500851T3 (ja) |
ES (1) | ES2072617T3 (ja) |
FI (1) | FI103015B (ja) |
GR (1) | GR3015719T3 (ja) |
HU (1) | HU206824B (ja) |
IL (1) | IL99237A (ja) |
IN (1) | IN171740B (ja) |
NO (1) | NO303669B1 (ja) |
PT (1) | PT98758B (ja) |
SK (1) | SK278919B6 (ja) |
WO (1) | WO1992003126A1 (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5472714A (en) * | 1993-09-08 | 1995-12-05 | Ciba-Geigy Corporation | Double-layered oxcarbazepine tablets |
US5399356A (en) * | 1994-03-24 | 1995-03-21 | The Procter & Gamble Company | Process for making solid dose forms containing bismuth |
US5948438A (en) * | 1995-01-09 | 1999-09-07 | Edward Mendell Co., Inc. | Pharmaceutical formulations having improved disintegration and/or absorptivity |
US6936277B2 (en) * | 1995-01-09 | 2005-08-30 | J. Rettenmaier & Soehne Gmbh & Co. Kg | Pharmaceutical excipient having improved compressibility |
IL116674A (en) * | 1995-01-09 | 2003-05-29 | Mendell Co Inc Edward | Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof |
US5585115A (en) * | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
US6395303B1 (en) | 1996-06-10 | 2002-05-28 | Edward Mendell Co., Inc. | Process for preparing a directly compressible solid dosage form containing microcrystalline cellulose |
US6471994B1 (en) | 1995-01-09 | 2002-10-29 | Edward Mendell Co., Inc. | Pharmaceutical excipient having improved compressibility |
US6852336B2 (en) | 1995-11-15 | 2005-02-08 | J. Rettenmaier & Soehne Gmbh + Co. Kg | Directly compressible high load acetaminophen formulations |
US5733578A (en) * | 1995-11-15 | 1998-03-31 | Edward Mendell Co., Inc. | Directly compressible high load acetaminophen formulations |
US6391337B2 (en) | 1995-11-15 | 2002-05-21 | Edward Mendell Co., Inc. | Directly compressible high load acetaminophen formulations |
EP0901787B1 (en) * | 1997-09-10 | 2003-05-28 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
GB9910505D0 (en) * | 1999-05-06 | 1999-07-07 | Electrosols Ltd | A method and apparatus for manufacturing consumable tablets |
ES2262528T3 (es) * | 1999-08-04 | 2006-12-01 | Astellas Pharma Inc. | Composiciones medicinales estables para administracion oral que utilizan oxidos de hierro. |
US6989159B2 (en) * | 2000-08-10 | 2006-01-24 | Jds Pharmaceuticals, Llc | Pharmaceutical compositions containing lithium carbonate |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3907999A (en) * | 1968-01-30 | 1975-09-23 | Merck & Co Inc | Substituted dibenzocyclooctene compositions |
NL167153C (nl) * | 1968-12-24 | 1981-11-16 | Merck & Co Inc | Werkwijze voor het bereiden of vervaardigen van een farmaceutisch preparaat en werkwijze voor het bereiden van een farmacologisch werkzaam, aan het stikstofatoom gesubstitueerd 5-aminomethyl-5-hydroxy-5h-dibenzoÿa.dÿ- cyclohepteen, geschikt voor gebruik bij de genoemde werkwijze. |
DE2416903A1 (de) * | 1974-04-06 | 1975-10-09 | Bayer Ag | Verwendung von schmelzverspruehtem kugelfoermigem phenacetingranulat zur herstellung von tabletten im direkttablettierverfahren |
US4198402A (en) * | 1975-12-17 | 1980-04-15 | Richter Gedeon Vegyeszeti Gyar Rt. | Antiphlogistic composition of phenylbutozone and alkali salicylate and method of treatment |
EP0112061A3 (en) * | 1982-11-20 | 1985-08-14 | Beecham Group Plc | Pharmaceutical or veterinary compositions containing guanoxabenz |
US4517179A (en) * | 1983-04-29 | 1985-05-14 | Pennwalt Corporation | Rapid dissolving, uniform drug compositions and their preparation |
CA1261261A (en) * | 1985-03-08 | 1989-09-26 | Dev K. Mehra | Coprocessed microcrystalline cellulose and calcium carbonate composition and its preparation |
US4707361A (en) * | 1985-08-02 | 1987-11-17 | Stauffer Chemical Company | Granular anhydrous dicalcium phosphate compositions suitable for direct compression tableting |
-
1990
- 1990-08-24 HU HU905314A patent/HU206824B/hu unknown
-
1991
- 1991-08-20 IN IN629/MAS/91A patent/IN171740B/en unknown
- 1991-08-20 IL IL9923791A patent/IL99237A/en not_active IP Right Cessation
- 1991-08-23 PT PT98758A patent/PT98758B/pt not_active IP Right Cessation
- 1991-08-23 CZ CS912617A patent/CZ281577B6/cs not_active IP Right Cessation
- 1991-08-23 KR KR1019920700937A patent/KR0177493B1/ko not_active IP Right Cessation
- 1991-08-23 WO PCT/HU1991/000039 patent/WO1992003126A1/en active IP Right Grant
- 1991-08-23 ES ES91915256T patent/ES2072617T3/es not_active Expired - Lifetime
- 1991-08-23 AT AT91915256T patent/ATE119388T1/de not_active IP Right Cessation
- 1991-08-23 JP JP3513683A patent/JPH0813736B2/ja not_active Expired - Fee Related
- 1991-08-23 US US07/849,067 patent/US5322698A/en not_active Expired - Lifetime
- 1991-08-23 DE DE69108007T patent/DE69108007T2/de not_active Expired - Lifetime
- 1991-08-23 SK SK2617-91A patent/SK278919B6/sk not_active IP Right Cessation
- 1991-08-23 EP EP91915256A patent/EP0500851B1/en not_active Expired - Lifetime
- 1991-08-23 DK DK91915256.1T patent/DK0500851T3/da active
- 1991-09-23 CA CA002067733A patent/CA2067733C/en not_active Expired - Lifetime
-
1992
- 1992-04-23 NO NO921569A patent/NO303669B1/no not_active IP Right Cessation
- 1992-04-23 FI FI921809A patent/FI103015B/fi not_active IP Right Cessation
-
1995
- 1995-04-10 GR GR950400851T patent/GR3015719T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
FI921809A0 (fi) | 1992-04-23 |
SK278919B6 (sk) | 1998-04-08 |
DE69108007T2 (de) | 1995-07-20 |
KR0177493B1 (ko) | 1999-03-20 |
FI103015B1 (fi) | 1999-04-15 |
PT98758B (pt) | 1999-01-29 |
FI921809A (fi) | 1992-04-23 |
EP0500851B1 (en) | 1995-03-08 |
US5322698A (en) | 1994-06-21 |
WO1992003126A1 (en) | 1992-03-05 |
KR927002214A (ko) | 1992-09-03 |
ATE119388T1 (de) | 1995-03-15 |
CZ281577B6 (cs) | 1996-11-13 |
IN171740B (ja) | 1992-12-26 |
CS261791A3 (en) | 1992-03-18 |
EP0500851A1 (en) | 1992-09-02 |
NO303669B1 (no) | 1998-08-17 |
PT98758A (pt) | 1992-07-31 |
HU206824B (en) | 1993-01-28 |
DK0500851T3 (da) | 1995-07-24 |
CA2067733C (en) | 2002-03-19 |
JPH0813736B2 (ja) | 1996-02-14 |
DE69108007D1 (de) | 1995-04-13 |
CA2067733A1 (en) | 1992-02-25 |
GR3015719T3 (en) | 1995-07-31 |
HU905314D0 (en) | 1991-02-28 |
IL99237A0 (en) | 1992-07-15 |
NO921569D0 (no) | 1992-04-23 |
IL99237A (en) | 1996-01-19 |
NO921569L (no) | 1992-04-23 |
FI103015B (fi) | 1999-04-15 |
ES2072617T3 (es) | 1995-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3773920A (en) | Sustained release medicinal composition | |
ES2334933T3 (es) | Comprimido recubierto o granulado que contiene una piridilpirimidina. | |
JPH05503540A (ja) | 単斜結晶構造を有する熱―、光―、及び湿気―感受性活性成分を含む錠剤又は糖剤組成物の調製方法 | |
CZ288545B6 (cs) | Stabilizovaná farmaceutická kompozice na bázi kyseliny (E)-3,5-dihydroxy-7-[4´-4´´-fluorfenyl-2´-cyklopropylchinolin-3´-yl]-6-heptenové | |
HU198385B (en) | Process for producing peroral pharmaceutical compositions containing acid-sensitive benzimidazol derivatives for treating gastrointestinal illnesses | |
JPS5839618A (ja) | 持続性積層錠剤 | |
JPH0237327B2 (ja) | ||
JP2009524658A (ja) | レベチラセタム製剤、及びそれらの製造方法 | |
PT2468361E (pt) | Formulações de vildagliptina | |
EP0013131A2 (en) | Pharmaceutical composition in solid dosage form, and process for its production | |
JPS60152411A (ja) | 経口投与のための遅延作用アセチルサリチル酸製剤 | |
SU1009467A1 (ru) | Средство дл растворени мочевых конкрементов | |
MX2011002400A (es) | Preparacion farmaceutica solida que tiene ingredientes activos separados por limites en la misma. | |
CN112516159A (zh) | 一种含有硝酸盐的组合物、胃漂浮剂及制备方法和应用 | |
US3039922A (en) | Method of administering tablets having decongestant and anti-histaminic activity | |
JPS5948810B2 (ja) | ニカルジピン持続性製剤用組成物 | |
JPS60252415A (ja) | サリチル酸コリンを含有する安定な固体薬剤用組成物 | |
HU191542B (en) | Process for production of pastiles containing dipyridamel independent from ph with regulated output of the active substance | |
GB2061111A (en) | Long acting pharmaceutical composition | |
JPH11335302A (ja) | 安定な医薬組成物 | |
JPH02286614A (ja) | アセトアミノフェン製剤 | |
JP2012140413A (ja) | ロキソプロフェンナトリウムとビタミンb1を含有する固形製剤 | |
JPH08193027A (ja) | 昇華イブプロフェンの再結晶防止方法 | |
JPS6024766B2 (ja) | 徐放性抗生物質錠 | |
JP2006328001A (ja) | 経口投与用製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080214 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090214 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090214 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100214 Year of fee payment: 14 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100214 Year of fee payment: 14 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110214 Year of fee payment: 15 |
|
LAPS | Cancellation because of no payment of annual fees |